Researchers race less-toxic cancer drugs for Australian children
Australian researchers are developing cancer treatments just as powerful but far less toxic, with federal funding for CAR-T trials.
More than 1000 children are diagnosed with cancer each year in Australia, with survival rates now exceeding 80 per cent. Most survivors face lifelong health effects from treatments originally designed for adults, about two in three.
Children like Wyatt, left permanently deaf in one ear after two years of leukaemia treatment, and Theodore, who endured 800 days of critical illness, carry that cost. The new frontier includes immunotherapy, cellular therapies and cancer vaccines designed to attack cancer more precisely while protecting the rest of the body.
The federal investment brings international CAR-T trials closer to home, giving more Australian families access to cutting-edge treatment without travelling overseas.
- 1000+
- Children diagnosed yearly
- exceeding 80 per cent
- Survival rate
- about two in three
- Survivors with long-term effects
- $5 million
- Federal CAR-T investment
Why it mattersFor Australian families with a child facing cancer, this means access to less toxic treatments that reduce lifelong disability and health complications.
AustraliaThe $5 million federal investment brings advanced CAR-T immunotherapy trials to Australia, giving more Australian children access to less toxic treatments closer to home.
✓ Claims checked against the source. checked 10 h ago
Open this story in InSnip →
